Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sana Biotechnology Inc (NQ: SANA )

1.890 -0.150 (-7.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,367,987
Open 2.000
Bid (Size) 1.890 (11)
Ask (Size) 1.940 (10)
Prev. Close 2.040
Today's Range 1.810 - 2.040
52wk Range 1.810 - 12.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at December 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire

Performance

YTD
-55.00%
-55.00%
1 Month
-28.95%
-28.95%
3 Month
-57.72%
-57.72%
6 Month
-68.91%
-68.91%
1 Year
-52.63%
-52.63%

More News

Read More
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sana Biotechnology to Present at September 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
From Sana Biotechnology, Inc
Via GlobeNewswire
SANA Stock Earnings: Sana Biotechnology Misses EPS for Q2 2024
Via InvestorPlace
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other
From Sana Biotechnology, Inc
Via GlobeNewswire
SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024
Via InvestorPlace
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at May and June 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sana Biotechnology, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.